Immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccination in exposed and potentially exposed persons in the Democratic Republic of the Congo

Partnership for Research on Ebola VACcination (PREVAC): protocol of a randomized, double-blind, placebo-controlled phase 2 clinical trial evaluating three vaccine strategies against Ebola in healthy volunteers in four West African countries

(2021) Moses Badio et al.   Trials

Disrupting vaccine logistics

(2021) Eric R James   International Health

Ebola Virus Transmission Initiated by Relapse of Systemic Ebola Virus Disease

(2021) Placide Mbala-Kingebeni et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, immunogenicity and risk–benefit analysis of rVSV-ΔG-ZEBOV-GP (V920) Ebola vaccine in Phase I–III clinical trials across regions

(2020) Bache Emmanuel Bache et al.   Future Microbiology

Population Movement Patterns Among the Democratic Republic of the Congo, Rwanda, and Uganda During an Outbreak of Ebola Virus Disease: Results from Community Engagement in Two Districts — Uganda, March 2019

(2020) Lydia Nakiire et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

Improving Vaccine-Induced Immunity: Can Baseline Predict Outcome?

(2020) John S. Tsang et al.   TRENDS IN IMMUNOLOGY

Development, qualification, and validation of the Filovirus Animal Nonclinical Group anti-Ebola virus glycoprotein immunoglobulin G enzyme-linked immunosorbent assay for human serum samples

(2019) Thomas L. Rudge et al.   PLoS One

Ebola Virus in the Democratic Republic of the Congo

(2019) Julie Erb-Alvarez et al.   CHEST

Immunosenescence and human vaccine immune responses

(2019) Stephen N. Crooke et al.   Immunity & Ageing

Ebola virus vaccine receives prequalification

(2019) Talha Burki   LANCET

Knowledge and beliefs about Ebola virus in a conflict-affected area: early evidence from the North Kivu outbreak

(2019) Ben Oppenheim et al.   Journal of Global Health

From discovery to delivery: public sector development of the rVSV-ZEBOV Ebola vaccine

(2019) Matthew Herder et al.   Journal of Law and the Biosciences

Serologic Evidence of Ebolavirus Infection in a Population With No History of Outbreaks in the Democratic Republic of the Congo

(2018) Sabue Mulangu et al.   JOURNAL OF INFECTIOUS DISEASES

Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study

(2018) Angela Huttner et al.   LANCET INFECTIOUS DISEASES

Serologic Markers for Ebolavirus Among Healthcare Workers in the Democratic Republic of the Congo

(2018) Nicole A Hoff et al.   JOURNAL OF INFECTIOUS DISEASES

Sex differences in vaccine-induced humoral immunity

(2018) Stephanie Fischinger et al.   Seminars in Immunopathology

Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!)

(2017) Ana Maria Henao-Restrepo et al.   LANCET

Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study

(2017) D Gray Heppner et al.   LANCET INFECTIOUS DISEASES

A Recombinant Vesicular Stomatitis Virus Ebola Vaccine

(2017) Jason A. Regules et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase 2 Placebo-Controlled Trial of Two Vaccines to Prevent Ebola in Liberia

(2017) Stephen B. Kennedy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Considerations for use of Ebola vaccine during an emergency response

(2017) Jenny A. Walldorf et al.   VACCINE

A systematic review and meta-analysis of seroprevalence surveys of ebolavirus infection

(2017) Hilary Bower et al.   Scientific Data

High prevalence of IgG antibodies to Ebola virus in the Efé pygmy population in the Watsa region, Democratic Republic of the Congo

(2016) Sabue Mulangu et al.   BMC INFECTIOUS DISEASES

Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe

(2016) Selidji T. Agnandji et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ebola vaccines in clinical trial: The promising candidates

(2016) Yuxiao Wang et al.   Human Vaccines & Immunotherapeutics

Cross-Border Cholera Outbreaks in Sub-Saharan Africa, the Mystery behind the Silent Illness: What Needs to Be Done?

(2016) Godfrey Bwire et al.   PLoS One

How sex and age affect immune responses, susceptibility to infections, and response to vaccination

(2015) Carmen Giefing-Kröll et al.   AGING CELL

Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial

(2015) Ana Maria Henao-Restrepo et al.   LANCET

The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial

(2015) Angela Huttner et al.   LANCET INFECTIOUS DISEASES

Emergency Ebola response: a new approach to the rapid design and development of vaccines against emerging diseases

(2015) Claire M Tully et al.   LANCET INFECTIOUS DISEASES

Sex and Gender Impact Immune Responses to Vaccines Among the Elderly

(2015) Ashley L. Fink et al.   PHYSIOLOGY

Sex-based differences in immune function and responses to vaccination

(2015) S. L. Klein et al.   TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE

Gender effects on humoral immune responses to smallpox vaccine

(2009) Richard B. Kennedy et al.   VACCINE

Age-related decline in immunity: implications for vaccine responsiveness

(2008) Rajesh Kumar et al.   Expert Review of Vaccines

Vesicular Stomatitis Virus-Based Ebola Vaccine Is Well-Tolerated and Protects Immunocompromised Nonhuman Primates

(2008) Thomas W. Geisbert et al.   PLoS Pathogens